grade
pharmaceutical primary standard
API family
folic acid
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC1=NC(=O)C2=NC(CNc3ccc(cc3)C(O)=O)=CNC2=N1
InChI
1S/C14H12N6O3/c15-14-19-11-10(12(21)20-14)18-9(6-17-11)5-16-8-3-1-7(2-4-8)13(22)23/h1-4,6,16H,5H2,(H,22,23)(H3,15,17,19,20,21)
InChI key
JOAQINSXLLMRCV-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Folic acid impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 叶酸杂质D
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Michael S Lee et al.
The journal of physical chemistry. B, 112(42), 13411-13417 (2008-09-30)
A comparative analysis is provided of the effect of different solvent models on the calculation of a potential of mean force (PMF) for determining the absolute binding affinity of the small molecule inhibitor pteroic acid bound to ricin toxin A-chain
C E Butterworth et al.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 181(1), 49-58 (1986-01-01)
"No-blood disease" is a severe, feed-related anemia of channel catfish. Pathological features in advanced cases include almost total absence of circulating red blood cells, hepatic fatty change, megaloblastic arrest of hematopoiesis, and intussusceptions of the small intestine. In view of
G Steinberg et al.
Journal of medicinal chemistry, 44(1), 69-73 (2001-01-05)
A novel nitroheterocyclic bis(haloethyl)phosphoramidate prodrug linked through lysine to a pteroic acid has been prepared and evaluated as a potential alkylating agent to target tumor cells that overexpress the folate receptor. The prodrug exhibited IC(50) values in the micromolar range
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| Y0001243 | 04061833806715 |